82 related articles for article (PubMed ID: 11883038)
1. [Interview with Professor Dr. Volker Diehl, Cologne. Hodgkin disease: on the path to causal therapy? (interview by Christine Vetter)].
Diehl V
MMW Fortschr Med; 2002 Jan; 144(5):8. PubMed ID: 11883038
[No Abstract] [Full Text] [Related]
2. Apoptosis-resistant phenotype of classical Hodgkin's lymphoma is not mediated by somatic mutations within genes encoding members of the death-inducing signaling complex (DISC).
Thomas RK; Schmitz R; Harttrampf AC; Abdil-Hadi A; Wickenhauser C; Distler V; Hansmann ML; Schultze JL; Küppers R; Wolf J
Leukemia; 2005 Jun; 19(6):1079-82. PubMed ID: 15815717
[No Abstract] [Full Text] [Related]
3. The pathogenetic significance of deregulated signal transduction pathways in Hodgkin's disease: the NF-kappaB-AP-1 network.
Scheidereit C
Verh Dtsch Ges Pathol; 2003; 87():79-89. PubMed ID: 16888898
[TBL] [Abstract][Full Text] [Related]
4. [The molecular pathogenesis of classical Hodgkin lymphoma].
Mathas S; Dörken B; Janz M
Dtsch Med Wochenschr; 2009 Sep; 134(39):1944-8. PubMed ID: 19760557
[TBL] [Abstract][Full Text] [Related]
5. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.
Guo F; Sun A; Wang W; He J; Hou J; Zhou P; Chen Z
Mol Immunol; 2009 Aug; 46(13):2441-8. PubMed ID: 19540595
[TBL] [Abstract][Full Text] [Related]
6. [Current views of the histogenesis and pathogenesis of Hodgkin lymphoma].
Leenman EE
Arkh Patol; 2007; 69(5):7-11. PubMed ID: 18074812
[TBL] [Abstract][Full Text] [Related]
7. Classical Hodgkin lymphoma concurrently evolving in a patient with marginal zone B-cell lymphoma of the spleen.
Harada S; Kalla H; Balasubramanian M; Brodsky I; Gladstone D; Hou JS
Ann Diagn Pathol; 2008 Jun; 12(3):212-6. PubMed ID: 18486899
[TBL] [Abstract][Full Text] [Related]
8. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma.
Hertel CB; Zhou XG; Hamilton-Dutoit SJ; Junker S
Oncogene; 2002 Jul; 21(32):4908-20. PubMed ID: 12118370
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle and apoptosis deregulation in classical Hodgkin lymphomas.
Bai M; Papoudou-Bai A; Kitsoulis P; Horianopoulos N; Kamina S; Agnantis NJ; Kanavaros P
In Vivo; 2005; 19(2):439-53. PubMed ID: 15796209
[TBL] [Abstract][Full Text] [Related]
10. [Signal(s) from B cell antigen receptors and apoptotic cell death of immature B cells].
Koga R; Doi T; Watanabe T
Tanpakushitsu Kakusan Koso; 2002 Dec; 47(16 Suppl):2274-8. PubMed ID: 12518448
[No Abstract] [Full Text] [Related]
11. The Hodgkin and Reed/Sternberg cell.
Küppers R; Hansmann ML
Int J Biochem Cell Biol; 2005 Mar; 37(3):511-7. PubMed ID: 15618006
[TBL] [Abstract][Full Text] [Related]
12. [B cell signal transduction and autoimmunity].
Fujimoto M
Nihon Rinsho Meneki Gakkai Kaishi; 2002 Jun; 25(3):244-54. PubMed ID: 16578969
[No Abstract] [Full Text] [Related]
13. Defective Bax activation in Hodgkin B-cell lines confers resistance to staurosporine-induced apoptosis.
Kashkar H; Krönke M; Jürgensmeier JM
Cell Death Differ; 2002 Jul; 9(7):750-7. PubMed ID: 12058280
[TBL] [Abstract][Full Text] [Related]
14. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma.
Staber PB; Noehammer C; Dürkop H; Schauer S; Kenner L; Linkesch W; Hoefler G
Leuk Res; 2006 Mar; 30(3):343-8. PubMed ID: 16198418
[TBL] [Abstract][Full Text] [Related]
15. Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells.
Tur MK; Neef I; Jost E; Galm O; Jäger G; Stöcker M; Ribbert M; Osieka R; Klinge U; Barth S
J Immunother; 2009 Jun; 32(5):431-41. PubMed ID: 19609235
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
17. [Molecular basis of Hodgkin lymphoma and anaplastic large cell lymphoma and molecular targeting therapy by an NF-kappaB inhibitor].
Horie R
Rinsho Ketsueki; 2007 Apr; 48(4):255-61. PubMed ID: 17515115
[No Abstract] [Full Text] [Related]
18. Overview of the Sixth International Symposium on Hodgkin's disease--recent advances in basic and clinical trials.
Josting A; Heidecke C; Dieh V
Eur J Haematol Suppl; 2005 Jul; (66):1-5. PubMed ID: 16007861
[TBL] [Abstract][Full Text] [Related]
19. Dysfunction of the Fas apoptotic signaling pathway in persistent polyclonal B-cell lymphocytosis.
Roussel M; Roué G; Sola B; Mossafa H; Troussard X
Haematologica; 2003 Feb; 88(2):239-40. PubMed ID: 12604424
[No Abstract] [Full Text] [Related]
20. [Pathology of Hodgkin's lymphoma].
Hansmann ML; Willenbrock K
Verh Dtsch Ges Pathol; 2003; 87():53-7. PubMed ID: 16888894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
